News
-
-
-
COMMUNIQUÉ DE PRESSE
Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December
Immunic to participate in the 8th Annual Evercore ISI Healthcare Conference in December. Dr. Daniel Vitt to speak at fireside chat on novel oral therapies for neurologic and gastrointestinal diseases -
-
-
COMMUNIQUÉ DE PRESSE
Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Immunic, Inc. reports Q3 2025 financial results and provides corporate update, highlighting vidofludimus calcium's therapeutic potential in multiple sclerosis. Phase 3 ENSURE trial data expected by 2026 -
-
-
-